One unexpected result was that some
hyperprolific authors placed many publica-
tions in a single journal. Prominent in this
regard were Acta Crystallographica Section E:
Structure Reports Online (relaunched in 2014
as Section E: Crystallographic Communica-
tions, with brief structural data reports now
published in IuCrData) and Zeitschrift für
Kristallographie New Crystal Structures. Three
authors have each published more than 600
articles in the former (Hoong-Kun Fun, Seik
Weng Ng and Edward Tiekink); three authors
have each published more than 400 papers in
the latter (Karl Peters, Eva Maria Peters and
Edward Tiekink). Three other authors (Anne
Marie Api, Charlene Letizia, Sneha Bhatia)
published many papers in single supplement
issues of Food and Chemistry Toxicology
focused on reviews of fragrance materials.
Journals indexed in Scopus are generally
considered to be quality journals. The cita-
tion impact of hyperprolific authors was
usually high, but there was large variability:
with a median of 19,805 citations per author
(range: 380 to 200,439). The median num-
ber of full papers per hyperprolific author in
2000–2016 was 677; across all hyperprolific
authors, last author positions accounted for
42.5%, first author positions for 7.1%, and
single authorships for 1.4%. Across the years,
the median proportion of papers with mid-
dle author positions (that is, not a single,
first or last author) was 51%, but varied from
2.1% to 98.5% for individual authors.
Our work to identify hyperprolific authors
is admittedly crude. It is mainly intended to
raise the larger question of what authorship
entails. Whether and how authorship is jus-
tified unavoidably varies for each author
and each paper, and norms differ by field.
It is likely that sometimes authorship can be
gamed, secured through coercion or pro-
vided as a favour. We could not assess these
patterns in our data. We did not examine
contributorship statements
8
, which are not
archived in Scopus. Nevertheless, even con-
tributorship statements can be gamed and
might not be accurate.
Further work is needed to explore how
to best normalize these data and what is the
optimal level of normalization: for example,
adjusting for wide discipline, relatively nar-
row field and/or highly specific research team.
WHAT AUTHORS SAY
To better understand authorship norms, we
e-mailed a survey to the 81 hyperprolific
authors of 2016 (see Supplementary Infor-
mation). We asked whether they fulfilled
all four Vancouver criteria. Of the 27 who
completed the survey, most said they did
not (see ‘Survey’). Almost all the responders
were from US and European institutions.
The only two responders from elsewhere
stated that they failed Vancouver criteria
in most of their papers. It is likely that the
survey underestimates the proportion not
meeting Vancouver criteria.
Not all authors had approved the final
versions of their own papers, but all consid-
ered approval of the final version necessary
for authorship. Fifty-nine per cent (16 of 27)
said that they had contributed more than
any other listed author for 25 or more of the
papers they authored in 2016.
Responses to the question “What, in
your own words, do you think should be
required for authorship?” generally reflected
a requirement for “significant contributions”,
but also dissatisfaction with how authorship
was assessed. One scientist said, “I person-
ally don’t count them as ‘my papers’ and
don’t have them on my CV as such, as there is
a distinction between being a ‘named author’
versus a ‘consortium member’ authorship.”
Another observed that authorship was often
awarded for seniority, and another that bet-
ter distinctions were essential. “I think there
should be levels of authorship — and not
those implied by order!” It will be interest-
ing to monitor how innovations in assign-
ing credit, such as data citation or formal
author contribution taxonomies, could alter
authorship conventions. Authorship norms
can vary within each field and even within
each team. For example, some teams in epi-
demiology and cardiology apparently offer
authorship more generously; others stick to
stricter (and probably more appropriate)
authorship criteria. For a similar task and
contribution, one cohort study might credit
20 authors, another might give credit only
to 3 people or none. For example, genome-
wide studies typically include many dozens
of authors. As a dramatic counter-example,
one recent publication of a genome-wide
study had only one author
9
, and apparently
that researcher did the same amount of work
for which perhaps dozens would get author-
ship credit in similar papers spearheaded by
different teams. Some evidence suggests
that the increase in the average number of
authors per paper does not reflect so much
the genuine needs of team science as the
pressure to ‘publish or perish’
10
.
Widely used citation and impact metrics
should be adjusted accordingly. For instance,
if adding more authors diminished the credit
each author received, unwarranted multi-
authorship might go down. We found that
the 30 hyperprolific authors who seemed to
benefit the most from co-authorship num-
bered 6 cardiologists and 24 epidemiologists
(including those working on population
genetics studies). (For these scientists, the
ratio of their Hirsch H index to their co-
authorship-adjusted Schreiber H
m
index was
higher; see Supplementary Information.)
Overall, hyperprolific authors might
include some of the most energetic and excel-
lent scientists. However, such modes of pub-
lishing might also reflect idiosyncratic field
norms, to say the least. Loose definitions of
authorship, and an unfortunate tendency
to reduce assessments to counting papers,
muddy how credit is assigned. One still needs
to see the total publishing output of each sci-
entist, benchmarked against norms for their
field. And of course, there is no substitute for
reading the papers and trying to understand
what the authors have done.
John P. A. Ioannidis is a professor of
medicine at the Meta-Research Innovation
Center at Stanford (METRICS), Stanford
University, California, USA. Richard
Klavans and Kevin W. Boyack are
researchers at SciTech Strategies in
Philadelphia, Pennsylvania, and
Albuquerque, New Mexico, USA.
e-mail: jioannid@stanford.edu
1. Wager, E., Singhvi, S. & Kleinert, S. PeerJ 3, e1154
(2015).
2. Quan, W., Chen, B. & Shu, F. Preprint at https://
arxiv.org/abs/1707.01162 (2017).
3. Hvistendahl, M. Science 342, 1035–1039 (2013).
4. Nature 483, 246 (2012).
5. Abritis, A., McCook, A. & Retraction Watch.
Science 357, 541 (2017).
6. Patience, G. S., Galli, F., Patience, P. A. &
Boffito, D. C. Preprint at bioRxiv https://doi.
org/10.1101/323519 (2018).
7. Drenth, J. J. Am. Med. Assoc. 280, 219–221
(1998).
8. Sauermann, H, & Haeussler, C. Sci. Adv. 3,
e1700404 (2017).
9. Kim, S. K. PLoS ONE 13, e0200785 (2018).
10. Papatheodorou, S. I., Trikalinos, T. A. & Ioannidis,
J. P. J. Clin. Epidemiol. 61, 546–551 (2008).
Supplementary Information accompanies this
Comment online (see go.nature.com/2phadg2).
HYPERPROLIFIC
AUTHORS PROLIFERATE
Numbers of authors with more than 72 papers
a year increased dramatically over time.
2002
2008
2016
= 1 author
4
39
81
SOURCE: J. P. A. IOANNIDIS, R. KLAVANS & K. W. BOYACK
13 SEPTEMBER 2018 | VOL 561 | NATURE | 169
COMMENT